Aggrastat Injection Strategy Trial Data Published in JAMA

Guilford Pharmaceuticals has published results from the STRATEGY trial of Aggrastat injection (tirofiban HCl) in The Journal of the American Medical Association.

The study found that a combination of Aggrastat and a drug-eluting stent (DES; sirolimus-eluting stent) resulted in a significantly lower rate of death, myocardial infarction, stroke and binary restenosis at eight months for patients with ST-elevation myocardial infarction, while also providing a similar cost of care when compared to abciximab used in combination with a bare metal stent.

Marco Valgimigli, principal investigator for the STRATEGY trial, said, "Our results demonstrate that tirofiban in combination with a drug-eluting stent (sirolimus-eluting stent) during primary percutaneous coronary intervention resulted in improved clinical and angiographic outcomes relative to a strategy of abciximab in combination with a bare metal stent. Moreover, there was a statistically significant reduction in the incidence of thrombocytopenia for patients receiving tirofiban and sirolimus eluting stent versus abciximab plus bare metal stent and a trend toward lower bleeding rates for patients treated with tirofiban and DES. Additional large scale trials, like TENACITY and MULTI-STRATEGY, will be needed to further evaluate the new single high-dose bolus regimen of tirofiban for these patients."